Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
MINEOLA, N.Y., March 12, 2026 (GLOBE NEWSWIRE) -- Hanover Bancorp, Inc. (NASDAQ: HNVR) (“Hanover” or “the Company”), parent company of Hanover Community Bank, is pleased to announce that the Company...
-
SUNNYVALE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- New global research from CyberEdge Group reveals a significant gap between organizations’ ability to detect attacks and their ability to contain...
-
GREENWICH, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Oxford Lane Capital Corp. (the “Company”) (Nasdaq GS: OXLC, OXLCP, OXLCL, OXLCO, OXLCZ, OXLCN, OXLCI and OXLCG) today announced that it plans to...
-
BLOOMINGTON, Ill., March 11, 2026 (GLOBE NEWSWIRE) -- HBT Financial, Inc. (NASDAQ: HBT) (the “Company” or “HBT Financial”), the holding company for Heartland Bank and Trust Company (“Heartland...
-
NORTHFIELD, Ill., March 10, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that it has closed its secondary offering of 86,250,000 shares of Medline Inc.’s Class A...
-
HOUSTON, TX, March 09, 2026 (GLOBE NEWSWIRE) -- Prairie Operating Co. (Nasdaq: PROP) (the “Company” or “Prairie”), an independent energy company engaged in the development and acquisition of oil and...
-
CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies...
-
Phase 1 clinical trial of SL-325 ongoing, with data expected in the second quarter of 2026 –Phase 2 clinical trial of SL-325 in patients with Crohn’s disease expected to initiate in the third quarter...
-
NORTHFIELD, Ill., March 04, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of a previously announced secondary offering of 75,000,000 shares of Medline...
-
$615 Million Acquisition of the Covelya Group Will Be Partially Financed Through a $350 Million Public Offering of Subscription Receipts Preliminary 2025 Year-End Results and Stand-Alone 2026...